Clinical Features, Prognosis, and Long-Term Response to Ranibizumab of Macular CNVs in Pattern Dystrophies Spectrum: A Pilot Study

Table 1

PD and AMD parameters at baseline and after 3 years.

	Baseline			3 years
	PD	AMD	value	PD	AMD	value
LogMAR, mean ± SD	0.55 ± 0.15	0.72 ± 0.44	0.13	0.86 ± 0.66	0.85 ± 0.58	0.95
CRT, µm, mean ± SD	413.66 ± 92.54	431.56 ± 142.39	0.13	365.90 ± 135.28	374.61 ± 162.27	0.85
SRF (%)	89.66	83.33	0.53	55.2	38.9	0.28
IRF (%)	31.03	44.44	0.35	37.9	38.9	0.95
SHRM (%)	69.0	66.7	0.87	48.3	61.1	0.39
HRF (%)	96.55	88.89	0.3	82.8	44.4	0.006
HCD (%)	0	0	-	10.3	5.6	0.57
cCT, µm, mean ± SD	214.14 ± 79.13	164.67 ± 45.81	0.009	186.66 ± 78.20	146.06 ± 48.33	0.033
slCT, µm, mean ± SD	211.44 ± 85.27	156.33 ± 53.07	0.009	183.52 ± 89.18	151.33 ± 58.08	0.14
EZd (%)	55.17	66.7	0.43	68.96	83.33	0.27
INJ N, mean ± SD	—	—	—	8.72 ± 1.16	7.28 ± 2.54	0.011

PD, pattern dystrophies; AMD, age-related macular degeneration; LogMAR, visual acuity; CRT, central retinal thickness; SRF, subretinal fluid; IRF, intraretinal fluid; SHRM, subretinal hyperreflective material; HRF, hyperreflective foci; HCD, hyperreflective crystalline deposits; cCT, central choroidal thickness; slCT, sublesional choroidal thickness; EZd, ellipsoid zone disruption; SD, standard deviation; µm, micrometer. The chi-square test is for quantitative data, and the unpaired-t test is for qualitative data.